We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Daily Rapid Lateral Flow COVID-19 Tests for Traced Contacts for Five Days Could Replace Requirement to Quarantine, Reveals Study

By LabMedica International staff writers
Posted on 25 Jan 2021
Print article
Image: Contact tracing app (Photo courtesy of Canva)
Image: Contact tracing app (Photo courtesy of Canva)
Additional testing with either a PCR or lateral flow antigen (LFA) test could potentially reduce the quarantine time of contacts of a confirmed case to seven days from the WHO recommended 14-day quarantine period without raising the risk of onward transmission, according to a new modeling study.

Researchers at the London School of Hygiene & Tropical Medicine (LSHTM; London, UK) conducted the study using mathematical modeling to estimate the effect of different quarantine and testing strategies on reducing onward transmission from traced secondary infections. The team simulated the levels of virus an infected person would be likely to produce at each stage of infection, alongside timing of symptom onset, test sensitivity and tracing and testing timings. The team estimate that completing the full 14-day recommended quarantine period for contacts of COVID-19 cases could prevent 59% of onward virus transmission. A similar proportion of onward transmission could potentially be prevented with only seven days of quarantine if a PCR or LFA test is performed on the final day of quarantine and people who receive a negative result are released.

The study estimates that the quarantine period could be replaced if traced contacts are required to take a daily LFA test for five days and those who do not receive any positive results are released, with 50% of onward virus transmission predicted to be prevented. If people adhere perfectly to self-isolation for the recommended 14 days after a positive test, and their close contacts taking a daily LFA test for five days and are then released on the final day if all tests are negative, the model estimates 80% of onward virus transmission could potentially be averted. Notably, the model is based on the assumption that the LFA test works at the higher level of sensitivity, detecting on average 76.8% of cases that tested positive in a PCR test.

“Our findings suggest that introducing testing of contacts in contact tracing may allow for a large reduction in the duration of quarantine,” said Billy Quilty, joint-lead author and Research Assistant at LSHTM. “Daily rapid tests for at least five days may allow for the quarantine requirement to be removed entirely, with self-isolation required only upon the onset of symptoms or a positive rapid test result. This strategy may allow for critical essential workers to continue working if exposed but not infected.”

Related Links:
London School of Hygiene & Tropical Medicine (LSHTM)

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.